A global health challenge

The chikungunya virus (chikv) is a mosquito origin alphavirus causing fever. Nevertheless, severe joint pain, rash and muscle ailments, mainly transmitted by Cashier mosquitoes. For example, In 2025. Consequently, the chikungunya epidemic centered on the islands of the Indian Ocean quickly extended to 119 countries, including temperate regions like France^1,2. Moreover, Control focuses on the management of vectors, monitoring, preparation for health care and international cooperation ^3,4. Meanwhile, Sino Biological supports research by providing antigens and recombinant chikv antibodies for vaccination, antiviral and diagnostic development.

What is chikungunya? – Global health challenge

The chikungunya virus is a RNA virus transmitted by mosquitoes belonging to the genus alphavirus. Moreover, Chikv infection leads to chikungunya fever. In addition, Infection is mainly transmitted to humans via infects bites Cashier mosquitoes, especially Aedesaegypti et Aedesalbopictus ^5,6. Therefore, Its symptoms include high sudden fever, severe joint pain, muscle pain, global health challenge rash and headache. For example, Although the disease is rarely fatal. In addition, it can be seriously debilitating, especially for the elderly, infants and those who suffer from underlying conditions. Meanwhile, There is currently no specific antiviral treatment for chikungunya ^3,7,8.

Figure 1. Meanwhile, Cycle of transmission of the chikungunya virus between humans and mosquitoes. Moreover, The virus is mainly distributed by mosquitoes from AEDES species (Stegomyia), mainly Aedes Aegypti and Aedes Albopictus. Therefore, Infected mosquitoes transmit the virus to humans through bites. For example, and infected humans can subsequently infect new mosquitoes, supporting the cycle of transmission ⁸. Moreover, Image credit: https://www.cdc.gov/chikungunya/php/transmission/index.html

Geographic spread. Furthermore, epidery of epidemic of 2025 – Global health challenge

Until now, the chikungunya epidemic has extended considerably to more than 110 countries, putting around 5.6 billion people in danger. In addition, Since the beginning of 2025, the reunion, Mayotte and Maurice global health challenge have all pointed out major epidemics of Chikungunya ^5,6,8. For example, In particular. Nevertheless, the virus has reached temperate regions earlier than before, with cases acquired locally reported in the continent regions in France and in the South-East ^8,9. Therefore, This wave is motivated by multiple factors. Therefore, especially Cashier Habitats of mosquitoes due to climate change, increased urbanization and international spread of travel facilitating the virus, populations with low immunity after years without epidemics and precocious detection challenges caused by inconsistent monitoring and limited diagnostic resources ^2,4.

Current. Meanwhile, vaccine treatment options for the chikungunya virus

In 2025, no specific antiviral treatment for the chikungunya virus existed; The care is favorable, by focusing on the relief of symptoms. Therefore, The progression of vaccines includes two approved options in certain countries: the IXCHIQ vaccine attenuated live for adults (with restrictions for the elderly). the vaccine by single global health challenge dose virus type for ages 12 and more ⁸. No vaccine is still widely available in the world or in China. The control is mainly based on mosquito management, early detection and public awareness.

The role of Sino Biological in support of research on the chikungunya virus

To combat the Mutant Chikv epidemic in progress. Sino Biological quickly launched the development of reecombinant E1 and E2 proteins (UVE / Chikv / 2024 / RE / CNR_79903) as well as specific antibodies, providing crucial support for researchers working on the development of vaccination, anti -viral therapies and of immunododiagnostic. Sino Biological offers key tools such as recombinant chikv e2 glycoprotein. clones of DNC and specialized antibodies for Elisa and LFA, all products under strict quality controls to ensure reliability.

Applications de Sino Biological’s pRoduct en rresearch

Sino Biological products are frequently mentioned in renowned journals. global health challenge Liu T. and Gu D. used the Recombinant Chikv E2 protein (Biological Sino. 40440-V08B) in a TRFIA test based on aptamer to study the affinity of bonds and the specificity of new peptides in the Chikv E2 antigens (Figure 2) ¹⁰.Tamburini B. et al. The acquisition of the viral antigen has studied in LEC. BEC and FRC cells in C57BL / 6 mice infected with a Recombinant Chikv E2 antigen (Sino Biological, 40440-V08B) combined with Alexafluor-488. They found that the LECs and a FRC subset acquired the Chikv E2 protein during the treatment window (Figure 3) ¹¹.Lim H. and Kim K. have shown that the protein EI / II Chikv. the Mutant Glycan proteins linked to N induces humoral immune responses lower than the protein E full length using mouse serums in a recombinant chikv E2 protein (Figure 4), 40440-V08B) Elisa Pre-Coated (Figure 4) ¹².Wang T. et al. reported that global health challenge EILV / CHIKV vaccinated macaques presented higher neutralization titles. higher chikv binding IgG responses in the ELISA CHIKV E2 Recombinant ENISA (Sino Biological, 40440-V08B) (Figure 5) (Figure 5) (Figure 5) (Figure 5) (Figure 5) (Figure 5) (Figure 5) (Figure 5) (Figure 5) (Figure 5) (Figure 5) (Figure 5) (Figure 5) (Figure 5) (Figure 5)¹³.

Figure 2. Detection of series diluted (0-1000 ng / ml) chikv-e2 recombinant (sino biological. 40440-V08B), Zika-e (Sino Biological, 40543-V08B4), Denv-e (biological sino, 40471-V08B) Proteins using peptide b2 and B3 aptowers ¹⁰.

Figure 3. Quantification of the frequency of LEC. BEC and FRC in the Popliteal lymph node (PLN) which are positive for the antigens RBD SARS-COV-2 and CHIKV-E2 Recombinant (Sino Biological, 40440-V08B) administered global health challenge with polyi: C and αcd40 at the time indicated ¹¹. Image credit: https://pmc.ncbi.nlm.nih.gov/articles/pmc10957963

Figure 4. Individual mouse serums have been diluted in series. total levels of total IgG specific to anti-Chikv-E2 protein were quantified using Elisa with a recombinant chikv E2 protein (Sino Biological, 40440-V08B) ¹². Image credit: https://pmc.ncbi.nlm.nih.gov/articles/pmc11511311/

​​​​​​​

Figure 5. Chikv E2’s IgG Liaison IGG responses to indicate points of time by Elisa. precoe with a recombinant Chikv E2 protein (Sino Biological, 40440-V08B) ¹³. Image credit: https://pmc.ncbi.nlm.nih.gov/articles/pmc11659317/

Global health challenge

CHIKV antigens featured

In the star of chikv antibodies

​​​​​​​

global health challenge

References

1. Zumla, A., Ntoumi, F., Ippolito, G. & Consortium, P. Chikungunya virus disease returns to Europe: a turning point for the world arboviral landscape. Lancet0(2025).
2. Roiz, D., Boussès, P., Simard, F., Paupy, C. & Fontenille, D. Transmission of Aboriginal Chikungunya and extreme climatic events in the south of France. Plos fect trop dis9(2015).
3. Control, for DP and. Global presentation of the virus disease of the Chikungunya virus virus. Pre -printed at (2025).
4. Virus and other emerging arthritogenic alphathians. Nat Rev Microbiol (2025) two: 10.1038 global health challenge / S41579-025-01177-8.
5. The World Health Organization raises concerns about the spread of the Chikungunya virus behind mosquitoes | Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/world-health-organization-meses-concern-bout-spread-mosquito-borne-chikungunya-2025-07-22/.
6. Update of the epidemiology of Chikungunya-June 2025. Https://www.who.int/publications/m/item/chikungunya-apidemiology-update-june-2025.
7. What is the chikungunya virus, how are countries like China? | Health news | Al Jazeera. https://www.aljazeera.com/news/2025/8/6/what-is-chikungunya-virus-how-are-countries-such-as-china-battling -it.
8. Zones to Risque de Chickunya | Virus ChickUnya | CDC. https://www.cdc.gov/chikungunya/data-maps/index.html.
9. FRUANCE, E. et al. Genomic overview on the re -emergence of the Chikungunya virus on the Reunion Island, France, 2024 to 2025. Eurosurveillance30(2025).
10. Liu, T. et al. Fluoro-Immuno-Album test based on peptide aptower for the diagnosis of chikv. Virol20(2023).
11. Doan, Ta et al. The archiving of the antigen induced by immunization improves the responses of T lymphocytes from local memory CD8 +. after an unrelated viral infection. NPJ vaccines9(2024).
12. Kim, K. et al. Immunogenicity analysis of the DNA vaccine of the chikungunya virus based on putative glycosylation sites linked to the global health challenge puttive. n of the envelope protein. Vaccines (Basel)12(2024).
13. Adam, A. et al. A chikungunya fever vaccine based on insect insects provides rapid and durable protection in cynomolgus macaques. NPJ vaccines9(2024).